Literature DB >> 12063259

Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C.

Andrew J Gale1, Alexander Tsavaler, John H Griffin.   

Abstract

The anticoagulant human plasma serine protease, activated protein C (APC), inhibits blood coagulation by specific inactivation of the coagulation cofactors factor Va (FVa) and factor VIIIa. Site-directed mutagenesis of residues in three surface loops of a positive exosite located on APC was used to identify residues that play a significant role in binding to FVa. Eighteen different residues were mutated to alanine singly, in pairs, or in triple mutation combinations. Mutant APC proteins were purified and characterized for their inactivation of FVa. Three APC residues were identified that provide major contributions to FVa interactions: Lys(193), Arg(229), and Arg(230). In addition, four residues made significant minor contributions to FVa interactions: Lys(191), Lys(192), Asp(214), and Glu(215). All of these residues primarily contribute to APC cleavage at Arg(506) in FVa and play a small role in the interaction of APC with the Arg(306) cleavage site. In conjunction with previously published work, these results define an extensive FVa binding site in the positive exosite of APC that is primarily involved in binding and cleaving at Arg(506) on FVa.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063259     DOI: 10.1074/jbc.M204363200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa.

Authors:  Lin Chen; Chandrashekhara Manithody; Likui Yang; Alireza R Rezaie
Journal:  Protein Sci       Date:  2004-02       Impact factor: 6.725

2.  Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX.

Authors:  Taketoshi Ogawa; Ingrid M Verhamme; Mao-Fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2005-04-13       Impact factor: 5.157

3.  Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.

Authors:  Yaoming Wang; Meenakshisundaram Thiyagarajan; Nienwen Chow; Itender Singh; Huang Guo; Thomas P Davis; Berislav V Zlokovic
Journal:  Stroke       Date:  2008-12-04       Impact factor: 7.914

4.  Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C.

Authors:  Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

Review 5.  Cytoprotective protein C pathways and implications for stroke and neurological disorders.

Authors:  Berislav V Zlokovic; John H Griffin
Journal:  Trends Neurosci       Date:  2011-02-25       Impact factor: 13.837

6.  Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.

Authors:  Yaoming Wang; Zhen Zhao; Nienwen Chow; Tracy Ali; John H Griffin; Berislav V Zlokovic
Journal:  Brain Res       Date:  2013-02-21       Impact factor: 3.252

7.  An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Authors:  Yaoming Wang; Zhenggang Zhang; Nienwen Chow; Thomas P Davis; John H Griffin; Michael Chopp; Berislav V Zlokovic
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

Review 8.  2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Authors:  John H Griffin; Laurent O Mosnier; José A Fernández; Berislav V Zlokovic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

9.  Variable contributions of basic residues forming an APC exosite in the binding and inactivation of factor VIIIa.

Authors:  Masahiro Takeyama; Jennifer M Wintermute; Chandrashekhara Manithody; Alireza R Rezaie; Philip J Fay
Journal:  Biochemistry       Date:  2013-03-22       Impact factor: 3.162

10.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.